ArticleGut2015
Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats.
Article in Gut, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Review
- PEDF Protects Endothelial Barrier Integrity during Acute Myocardial Infarction via 67LR.International journal of molecular sciences · 2023Article
- Pan-cancer analysis of osteogenesis imperfecta causing geneIntractable & rare diseases research · 2022Article
- Metabolic Reprogramming of Liver Fibrosis.Cells · 2021Review
- Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.Journal of hepatology · 2021Review
- Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects.Frontiers in molecular biosciences · 2021Review
- Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview.International journal of molecular sciences · 2020Review
- Flaming the fight against cancer cells: the role of microRNA-93.Cancer cell international · 2020Review
- Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CClFrontiers of medicine · 2019Article
- Hepatic microcirculation and mechanisms of portal hypertension.Nature reviews. Gastroenterology & hepatology · 2019Review
- Interplay Between Macrophages and Angiogenesis: A Double-Edged Sword in Liver Disease.Frontiers in immunology · 2019Review
- The effects of pigment epithelium-derived factor on atherosclerosis: putative mechanisms of the process.Lipids in health and disease · 2018Review
- Advances in therapeutic options for portal hypertension.Therapeutic advances in gastroenterology · 2018Review
- miR-93-3p inhibition suppresses clear cell renal cell carcinoma proliferation, metastasis and invasion.Oncotarget · 2017Article
- Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.Digestive diseases and sciences · 2017Article
- Novel treatment options for portal hypertension.Gastroenterology report · 2017Article
- PEDF mediates pathological neovascularization by regulating macrophage recruitment and polarization in the mouse model of oxygen-induced retinopathy.Scientific reports · 2017Article
- PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction.Oncotarget · 2016Article
- Pigment Epithelium-Derived Factor (PEDF) is a Determinant of Stem Cell Fate: Lessons from an Ultra-Rare Disease.Journal of developmental biology · 2015Article
- Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/Cellular and molecular gastroenterology and hepatology · 2015Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAntiangiogenic strategies have been proposed as a promising new approach for the therapy of portal hypertension and chronic liver disease. Pigment epithelium-derived factor (PEDF) is a powerful endogenous angiogenesis inhibitor whose role in portal hypertension remains unknown. Therefore, we aimed at determining the involvement of PEDF in cirrhotic portal hypertension and the therapeutic efficacy of its supplementation.
designPEDF expression profiling and its relationship with vascular endothelial growth factor (VEGF), neovascularisation and fibrogenesis was determined in bile duct-ligated (BDL) rats and human cirrhotic livers. The ability of exogenous PEDF overexpression by adenovirus-mediated gene transfer (AdPEDF) to inhibit angiogenesis, fibrogenesis and portal pressure was also evaluated in BDL rats, following prevention and intervention trials.
resultsPEDF was upregulated in cirrhotic human and BDL rat livers. PEDF and VEGF protein expression and localisation in mesentery and liver increased in parallel with portal hypertension progression, being closely linked in time and space with mesenteric neovascularisation and liver fibrogenesis in BDL rats. Furthermore, AdPEDF increased PEDF bioavailability in BDL rats, shifting the net balance in the local abundance of positive (VEGF) and negative (PEDF) angiogenesis drivers in favour of attenuation of portal hypertension-associated pathological neovascularisation. The antiangiogenic effects of AdPEDF targeted only pathological angiogenesis, without affecting normal vasculature, and were observed during early stages of disease. AdPEDF also significantly decreased liver fibrogenesis (through metalloproteinase upregulation), portosystemic collateralisation and portal pressure in BDL rats.
conclusionsThis study provides compelling experimental evidence indicating that PEDF could be a novel therapeutic agent worthy of assessment in portal hypertension and cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.